Skip to Content

Banzel (rufinamide) Disease Interactions

There are 4 disease interactions with Banzel (rufinamide):

Major

Anticonvulsants (Includes Banzel) ↔ Depression

Severe Potential Hazard, Moderate plausibility

Applies to: Depression

Antiepileptic drugs can increase depression and suicidal thoughts or behaviors in patients receiving these drugs for any indication. Patients should be monitored for the emergence or worsening of depression, suicidal thoughts and unusual changes in mood or behavior. Caregivers and family should be alert for the emergence or worsening of symptoms. Behaviors of concern should be reported immediately to the healthcare providers.

Major

Anticonvulsants (Includes Banzel) ↔ Liver Disease

Severe Potential Hazard, Moderate plausibility

Applies to: Liver Disease

Most anticonvulsants are primarily metabolized by the liver. Metabolic activity may be decreased in patients with liver disease, resulting in elevated drug levels and increased risk of toxicity. Therapy with anticonvulsants should be administered cautiously in patients with mild and moderate liver impairment. Therapy with these drugs is mostly not recommended in patients with severe liver impairment. Caution is also advised when treating patients with a history of liver disease, since the use of some anticonvulsants has been associated with hepatotoxicity. Baseline and periodic evaluation of liver function is recommended. Therapy should be discontinued and not readministered if evidence of liver damage is observed and felt to be drug-related.

References

  1. Swinburn BA, Croxson MS, Miller MV, Crawford KB "Carbamazepine induced granulomatous hepatitis." N Z Med J Mar (1986): 167
  2. Ponte CD "Carbamazepine-induced thrombocytopenia, rash, and hepatic dysfunction." Drug Intell Clin Pharm 17 (1983): 642-4
  3. Horowitz S, Patwardhan R, Marcus E "Hepatotoxic reactions associated with carbamazepine therapy." Epilepsia 29 (1988): 149-54
View all 22 references
Major

Anticonvulsants (Includes Banzel) ↔ Renal Dysfunction

Severe Potential Hazard, Moderate plausibility

Applies to: Renal Dysfunction

Most anticonvulsants are primarily excreted by the kidney. The plasma clearance may be decreased and the half-life prolonged in patients with impaired renal function. Therapy with anticonvulsants should be administered cautiously in patients with significant renal dysfunction. In most cases it is recommended to adjust the dosage in patients with CrCl <50 mL/min to half the usual starting dose and then increase slowly to achieve the desired clinical response. The renal function should be monitored regularly in patients receiving therapy.

References

  1. "Product Information. Trileptal (oxcarbazepine)" Novartis Pharmaceuticals, East Hanover, NJ.
Major

Rufinamide (Includes Banzel) ↔ Short Qt Syndrome

Severe Potential Hazard, Moderate plausibility

Applies to: Short QT Syndrome

Rufinamide can cause shortening of the QT interval. Its use is contraindicated in patients with Familial Short QT syndrome as this condition is associated with increased risk of sudden death and ventricular arrhythmias, particularly ventricular fibrillation.

Banzel (rufinamide) drug Interactions

There are 767 drug interactions with Banzel (rufinamide)

Banzel (rufinamide) alcohol/food Interactions

There is 1 alcohol/food interaction with Banzel (rufinamide)

Drug Interaction Classification

The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.

Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.

Do not stop taking any medications without consulting your healthcare provider.

Disclaimer: Every effort has been made to ensure that the information provided by Multum is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. Multum's information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill, knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2016 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.

Hide